An Ad5 [E1-, E2b-] platform carrying the TAA CEA(6D) induces CEA directed CMI responses in patients with advanced CEA-expressing colorectal cancer in a phase I/II clinical trial.

作者:Morse Michael A; Gabitzsch Elizabeth S; Xu Younong; Rajesh Dua; Nguyen Susan; Balcaitis Stephanie; Balint Joseph P Jr; Jones Frank
来源:Cancer Research.
DOI:10.1158/1538-7445.TUMIMM2012-A29
  • 出版日期2013-1-1

全文